In accordance with The Standards for Integrity and Independence, GW requires all planners, faculty, and others in control of educational content to disclose the absence or existence of all financial relationships (of any dollar amount) with any ineligible companies within the past 24 months. Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
GW reviews all disclosure statements to determine which financial relationships are relevant to the educational content of the accredited CE Activity. An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No Relevant Financial Relationships
Upon review of all collected information about financial relationships with ineligible companies, GW has determined that the following planners, faculty, staff, and others in control of educational content have no relevant financial relationships with ineligible companies.
Planners & Staff
Debra Lynn Day-Salvatore
Vin Lo Re
Disclosure of Relevant Financial Relationships
Upon review of all collected information about financial relationships with ineligible companies, GW has determined that the following planners, faculty, and others in control of educational content have relevant financial relationships with ineligible companies.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
All relevant financial relationships have been mitigated prior to the individual assuming their role in the activity.
Brynn Levy, faculty is a consultant for Igenomix
Elizabeth Kichula, faculty is on the Advisory Boards for: Biogen, Avexis, Scholar Rock, PTC Therapeutics, and Sarepta
Elizabeth Kichula, faculty is on the Speakers' Bureau for Genentech
Jim Goldberg, faculty has received Stock Options from Myriad Genetics
Katelynn Sagaser, faculty has received Stock Options from Juno Diagnostics
Mary Norton, faculty has received Research Support from